AllSci News
DBV Tech raises USD 150m as BLA imminent for peanut-allergy patch
DBV Technologies S.A. (Euronext: DBV, Nasdaq: DBVT), a Châtillon, France-based late-stage biopharmaceutical company, has filed a refreshed at-the-market...
Vogenx seeks public funding to advance SGLT1 candidate in metabolic disorders
Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company developing a treatment for a metabolic condition with no FDA-approved therapies,...
FDA grants Fast Track designation to 4TEEN4’s invobenitug for cardiogenic shock
4TEEN4 Pharmaceuticals GmbH, headquartered in Germany, announced receipt of US FDA Fast Track Designation for invobenitug (formerly procizumab), a monoclonal antibody in…
Inhibrx secures up to USD 325m in additional venture debt to fund pipeline through key catalysts
San Diego-based Inhibrx Biosciences (Nasdaq: INBX) entered into an amended loan agreement with Oxford Finance LLC, expanding its credit facility to a total...
Centauri launches first-in-human trial for dual-mechanism antibiotic
Centauri Therapeutics Limited has initiated a first-in-human clinical trial for CTX-187, a bifunctional antimicrobial designed to address...
J&J Q2 2026 Earnings Call: Milvexian timeline, FireFly Bio acquisition, and H2 pipeline catalysts
Johnson & Johnson (NYSE: JNJ) held its JNJ Q2 2026 earnings call on July 15, 2026, during which executives detailed plans to acquire South San...
Takeda showcases high-impact site efficacy for zasocitinib at AAD Innovation Academy
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) reported new secondary endpoint data from its two pivotal Phase III trials of zasocitinib...
China expands approval of SystImmune’s iza-bren into esophageal cancer
China’s National Medical Products Administration has approved izalontamab brengitecan (iza-bren) for adults with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose…
EU approves AbbVie’s Boey, introducing first short-duration botulinum toxin in Europe
The European Commission has approved Boey (trenibotulinumtoxinE), a botulinum neurotoxin serotype E developed by Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, for…
K8's dual inflammasome inhibitor approach reshapes geographic atrophy treatment expectations
Inflammasome Therapeutics reported six-month Phase 2 results showing its investigational drug K8 slowed geographic atrophy lesion growth by more than half...
InnoCare advances soficitinib toward China filing after positive Phase III atopic dermatitis trial
InnoCare Pharma Limited (HKEX: 09969) announced on July 15 that soficitinib (ICP-332), its internally developed oral TYK2 inhibitor, met the primary...
Bayer adds Henry Ford Health to expanding US clinical research network
Bayer and Detroit-based Henry Ford Health announced a clinical trials partnership designed to connect more patients with investigational medicines, positioning Henry Ford…
Aqemia unlocks new drug target in expanded Sanofi AI collaboration
Aqemia and Sanofi have expanded their multi-year drug discovery collaboration, with the France-based AI company announcing the nomination of a new therapeutic…
GSK drops camlipixant after mixed Phase III results derail chronic cough program
GSK reported that its CALM-1 and CALM-2 phase III trials of camlipixant produced mixed results in refractory chronic cough (RCC), with one study meeting its...
Jasper expands immunology reach Kira acquisition, USD 132m PIPE round
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has completed its acquisition of Cambridge, Massachusetts-based Kira Pharmaceuticals in an all-stock transaction,...
The AllSci Brief
Systematic R&D and deal news. Daily.